Author

L. E. Rosen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 3 Biochemistry· 1 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:host-pathogen & immune response· 7 Organism:human· 7 Assay:proteomics· 5 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

E. Cameroni· 7 shared D. Pinto· 6 shared J. E. Bowen· 6 shared K. Culap· 6 shared N. Czudnochowski· 6 shared S. Jaconi· 6 shared A. De Marco· 5 shared A. Telenti· 5 shared

Activity by Year

2020-2023 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

E. Cameroni

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Identifying and overcoming the sampling challenges in relative binding free energy calculations of a model protein:protein complex

I. Zhang, D. A. Rufa, I. Pulido, M. M. Henry, L. E. Rosen, K. Hauser, S. Singh, J. D. Chodera

This study identifies sampling challenges in protein:protein binding free energy calculations and demonstrates how to overcome them using alchemical methods and long simulations.

bioRxiv · Mar 7, 2023Biophysics

The potent broadly neutralizing antibody VIR-3434 controls Hepatitis B and D Virus infection and reduces HBsAg in humanized mice

F. A. Lempp, T. Volz, E. Cameroni, F. Benigni, J. Zhou, L. E. Rosen, J. Noack, F. Zatta, H. Kaiser, S. Bianchi, G. Lombardo, S. Jaconi, H. Imam, L. B. Soriaga, N. Passini, , M. A. Schmid

This paper identifies a potent anti-HBs mAb, VIR-3434, that neutralizes HBV and HDV and reduces HBsAg and viremia in human liver-chimeric mice.

bioRxiv · Sep 9, 2022Microbiology

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

M. McCallum, N. Czudnochowski, L. E. Rosen, S. K. Zepeda, J. E. Bowen, J. R. Dillen, A. Powell, T. Croll, J. Nix, H. W. Virgin, D. Corti, G. Snell, D. Veesler

This study determines the structural basis of SARS-CoV-2 Omicron's immune evasion and receptor engagement through cryo-EM and X-ray crystal structures of the spike and RBD bound to antibodies and ACE2.

bioRxiv · Dec 28, 2021Biochemistry

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

E. Cameroni, C. Saliba, J. E. Bowen, L. E. Rosen, K. Culap, D. Pinto, L. A. VanBlargan, A. De Marco, S. K. Zepeda, J. di Iulio, F. Zatta, H. Kaiser, J. Noack, N. Farhat, N. Czudnochowski, , P

This study shows that Omicron variant's spike protein has enhanced ACE2 binding and reduces neutralizing activity, but some broadly neutralizing antibodies remain effective.

bioRxiv · Dec 12, 2021Immunology

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

D. Pinto, M. M. Sauer, N. Czudnochowski, J. S. Low, M. A. Tortorici, M. P. Housley, J. Noack, A. C. Walls, J. E. Bowen, B. Guarino, L. E. Rosen, J. di Iulio, J. Jerak, H. Kaiser, S. Islam, , Lanzave

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

bioRxiv · May 9, 2021 · PreprintImmunology

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody

M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 7, 2021 · PreprintImmunology

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape

T. N. Starr, N. Czudnochowski, F. Zatta, Y.-J. Park, Z. Liu, A. Addetia, D. Pinto, M. Beltramello, P. Hernandez, A. J. Greaney, R. Marzi, W. G. Glass, I. Zhang, A. S. Dingens, J. E. Bowen, , Veesler

This study identifies antibodies against SARS-CoV-2 that balance neutralization potency and breadth, with some showing high resistance to viral escape.

bioRxiv · Apr 6, 2021 · PreprintMicrobiology

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

M. McCallum, J. Bassi, A. De Marco, A. Chen, A. C. Walls, J. Di Iulio, M. A. Tortorici, M.-J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, , D. Veesler

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

bioRxiv · Mar 31, 2021 · PreprintImmunology

The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity

E. C. Thomson, L. E. Rosen, J. G. Shepherd, R. Spreafico, A. da Silva Filipe, J. A. Wojcechowskyj, C. Davis, L. Piccoli, D. J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, , J. Nichols

The paper shows the N439K SARS-CoV-2 spike variant maintains replication fitness while evading antibody neutralization.

bioRxiv · Nov 4, 2020Microbiology